LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name  
   Organization/Lobbying Firm [ ]  Self Employed Individual [ ]  
   AstraZeneca Pharmaceuticals LP

2. Address
   Address1: 1800 CONCORD PIKE, P.O. BOX 15437  
   Address2:  
   City: WILMINGTON  
   State: DE  
   Zip Code: 19850-5437  
   Country: USA

3. Principal place of business (if different than line 2)
   City:  
   State:  
   Zip Code:  
   Country:  

4a. Contact Name: Jamie Bell  
   b. Telephone Number: 2023505550  
   c. E-mail: jamie.bell@astrazeneca.com  
   5. Senate ID#: 54073-12

6. House ID#: 349750000

7. Client Name: AstraZeneca Pharmaceuticals LP
   [ ] Self
   [ ] Check if client is a state or local government or instrumentality

8. Year: 2019  
   Q1 (1/1 - 3/31) [ ]  Q2 (4/1 - 6/30) [ ]  Q3 (7/1 - 9/30) [ ]  Q4 (10/1 - 12/31) [ ]

9. Check if this filing amends a previously filed version of this report [ ]

10. Check if this is a Termination Report [ ]
    Termination Date:  

11. No Lobbying Issue Activity [ ]

12. Lobbying
    INCOME relating to lobbying activities for this reporting period was:
    [ ] Less than $5,000
    [ ] $5,000 or more $__________
    Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations
    EXPENSE relating to lobbying activities for this reporting period were:
    [ ] Less than $5,000
    [ ] $5,000 or more $510,000.00

14. REPORTING
    Check box to indicate expense accounting method. See instructions for description of options.
    [ ] Method A. Reporting amounts using LDA definitions only
    [ ] Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
    [ ] Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature: Digitally Signed By: Jamie Bell  
Date: 1/21/2020 11:14:41 AM
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

- Value of Prescription Drugs
- Drug Pricing Transparency
- Oncology Care Model
- Personalized Medicine
- Diagnostics
- S. 1895, Lower Health Care Costs Act
- HR 3 Drug pricing bill
- Rebate Reform
- USMCA

17. House(s) of Congress and Federal agencies

- U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julie</td>
<td>Garner</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None
15. General issue area code MMM

16. Specific lobbying issues

<table>
<thead>
<tr>
<th>Specific lobbying issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare Part D Coverage and Reimbursement</td>
</tr>
<tr>
<td>Medicare Part D Non-Interference</td>
</tr>
<tr>
<td>Legislative proposals to change Medicare Part D</td>
</tr>
<tr>
<td>Medicare Part B coverage and reimbursement</td>
</tr>
<tr>
<td>Changes to the Medicaid Drug Rebate Program (AMP Cap)</td>
</tr>
<tr>
<td>Medicare Part B Intl. Pricing Index ANPRM –14 Day Rule</td>
</tr>
<tr>
<td>End State Renal Disease PPS</td>
</tr>
<tr>
<td>H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the</td>
</tr>
<tr>
<td>maximum rebate amount for single source drugs</td>
</tr>
<tr>
<td>Final Rule: Medicare and Medicaid Programs; Regulation to Require Drug Pricing</td>
</tr>
<tr>
<td>Transparency</td>
</tr>
</tbody>
</table>

17. House(s) of Congress and Federal agencies    ☐  Check if None

| U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services |
| (CMS), Health & Human Services - Dept of (HHS)                                      |

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julie</td>
<td>Garner</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☑  Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

- Medicare Part D coverage and reimbursement
- Value of Prescription Drugs, Senate & House
- Prescription Drug Importation, Senate & House
- Innovative Payment Models, Senate & House, CMS
- Price Transparency, Senate & House
- Legislative proposals to change Medicare Part D
- Medicaid and 340B issues & drug discount program
- International Pricing Index Model (IPI)
- H.R. 1499, Protecting Consumer Access to Generic Drugs Act
- S. 1416, Affordable prescriptions for Patients Act
- S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act
- NPRM: Importation of Prescription drugs

17. House(s) of Congress and Federal agencies

- U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julie</td>
<td>Garner</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above

- Check if None
15. General issue area code CPT

16. Specific lobbying issues

- FDA Patent Settlement legislation
- Intellectual property and patent issues
- S. 340, H.R. 965 CREATE Act
- S. 1209, REMEDY Act
- S. 1224, H.R. 2374, Stop STALLING Act

17. House(s) of Congress and Federal agencies 

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julie</td>
<td>Garner</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
City __________________________ State ______ Zip Code ______ Country ______

21. Client new principal place of business (if different than line 20)

City __________________________ State ______ Zip Code ______ Country ______

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>4</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ISSUE UPDATE
24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Principal Place of Business</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1  
2  
3  

FOREIGN ENTITIES

27. Add the following foreign entities:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Principal place of business</th>
<th>Amount of contribution for lobbying activities</th>
<th>Ownership percentage in client</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>%</td>
</tr>
</tbody>
</table>

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1  
2  
3  
4  
5  
6  

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

☐ No  ☐ Yes

<table>
<thead>
<tr>
<th>Lobbyist Name</th>
<th>Description of Offense(s)</th>
</tr>
</thead>
</table>